These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 566868)

  • 1. Lergotrile in the treatment of parkinsonism.
    Klawans HL; Goetz CG; Volkman P; Nausieda PA; Weiner WJ
    Neurology; 1978 Jul; 28(7):699-702. PubMed ID: 566868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
    JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxial response to dopaminergic agents in parkinsonism.
    Wiener WJ; Kramer J; Nausieda PA; Klawans HL
    Arch Neurol; 1978 Jul; 35(7):453-5. PubMed ID: 666596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lergotrile in Parkinson disease: further studies.
    Lieberman AN; Gopinathan G; Estey E; Kupersmith M; Goodgold A; Goldstein M
    Neurology; 1979 Feb; 29(2):267-72. PubMed ID: 34808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lergotrile in Parkinson's disease.
    Lieberman AN; Kupersmith M; Estey E; Goldstein M
    Lancet; 1976 Sep; 1(7984):515-6. PubMed ID: 74475
    [No Abstract]   [Full Text] [Related]  

  • 9. Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
    Teychenne PF; Rosin AJ; Plotkin CN; Calne DB
    Br J Clin Pharmacol; 1980 Jan; 9(1):47-50. PubMed ID: 6101955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ergot derivatives in the treatment of parkinsonism.
    Calne DB
    Fed Proc; 1978 Jun; 37(8):2207-9. PubMed ID: 658459
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of hyperprolactinemia with a new ergot derivative, lergotrile mesylate.
    Sherman BM; Swanson JA; Chapler FK
    Fertil Steril; 1978 Mar; 29(3):291-5. PubMed ID: 565303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease.
    Lieberman AN; Goldstein M; Leibowitz M
    N Y State J Med; 1988 Aug; 88(8):420-2. PubMed ID: 2902541
    [No Abstract]   [Full Text] [Related]  

  • 13. Ergot derivatives for Parkinsonism.
    Calne DB; Williams AC; Nutt JG; Neophytides A; Eisler T; Teychenne PF
    Med J Aust; 1978 Nov; 2(3 Suppl):25-6. PubMed ID: 34083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
    Schneider E; Baas H; Fischer PA; Japp G
    J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pergolide mesylate and idiopathic Parkinson disease.
    Tanner CM; Goetz CG; Glantz RH; Glatt SL; Klawans HL
    Neurology; 1982 Oct; 32(10):1175-9. PubMed ID: 6889702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
    Bell RD; Carruth A; Rosenberg RN; Boyar RM
    J Clin Endocrinol Metab; 1978 Oct; 47(4):807-11. PubMed ID: 45469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
    Serby M; Angrist B; Lieberman A
    Adv Biochem Psychopharmacol; 1980; 23():287-92. PubMed ID: 6104908
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
    Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.